ArticleNPJ schizophrenia2018
Risk of weight gain for specific antipsychotic drugs: a meta-analysis.
Article in NPJ schizophrenia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development.The lancet. Psychiatry · 2023Pooled it
- Antipsychotic dose reduction compared to dose continuation for people with schizophrenia.The Cochrane database of systematic reviews · 2022Pooled it
- Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Pooled it
- Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.Medical decision making : an international journal of the Society for Medical Decision Making · 2019Pooled it
- Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication.Brain imaging and behavior · 2024Trial
- Review
- Review
- Demographic and Clinical Correlates of Body Mass Index in Older Age Bipolar Disorder: Results from the GAGE-BD Project.Medicina (Kaunas, Lithuania) · 2026Article
- Effects of cariprazine on cholesterol, glucose, and weight in patients with schizophrenia: a systematic review and meta-analysis.Therapeutic advances in psychopharmacology · 2026Article
- Trajectory analysis of BMI increase induced by second-generation antipsychotics in first-episode schizophrenia: a secondary analysis based on CNFEST***.Schizophrenia (Heidelberg, Germany) · 2025Article
- Effects of Pharmaceutical Substances with Obesogenic Activity on Male Reproductive Health.International journal of molecular sciences · 2024Review
- Mechanism and treatments of antipsychotic-induced weight gain.International journal of obesity (2005) · 2023Review
- Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
- Association between antipsychotic medication and clinically relevant weight change: meta-analysis.BJPsych open · 2023Review
- High-dose olanzapine in treatment-resistant schizophrenia: a systematic review.Therapeutic advances in psychopharmacology · 2023Review
- Article
- Cost analysis of lurasidone for the treatment of schizophrenia in adolescents and adults within the United Kingdom.BMC health services research · 2022Article
- Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort.Basic & clinical pharmacology & toxicology · 2022Article
- The benefits of the Mediterranean diet in first episode psychosis patients taking antipsychotics.Toxicology reports · 2022Article
- Gait Alterations in the Prediction of Metabolic Syndrome in Patients With Schizophrenia: A Pilot Study With PODOSmart ® Insoles.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
People with schizophrenia are at considerably higher risk of cardiometabolic morbidity than the general population. Second-generation antipsychotic drugs contribute to that risk partly through their weight gain effects, exacerbating an already high burden of disease. While standard 'as-randomized' analyses of clinical trials provide valuable information, they ignore adherence patterns across treatment arms, confounding estimates of realized treatment exposure on outcome. We assess the effect of specific second-generation antipsychotics on weight gain, defined as at least a 7% increase in weight from randomization, using a Bayesian hierarchical model network meta-analysis with individual patient level data. Our data consisted of 14 randomized clinical trials contributing 5923 subjects (mean age = 39 [SD = 12]) assessing various combinations of olanzapine (n = 533), paliperidone (n = 3482), risperidone (n = 540), and placebo (n = 1368). The median time from randomization to dropout or trial completion was 6 weeks (range: 0-60 weeks). The unadjusted probability of weight gain in the placebo group was 4.8% across trials. For each 10 g chlorpromazine equivalent dose increase in olanzapine, the odds of weight gain increased by 5 (95% credible interval: 1.4, 5.3); the effect of risperidone (odds ratio = 1.6 [0.25, 9.1]) was estimated with considerable uncertainty but no different from paliperidone (odds ratio = 1.3 [1.2, 1.5]).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.